Table 1.
Activin A and follistatin levels in study groups, unadjusted and after sequential adjustment for potential cofounders.
Lean controls | Obese controls | SS | NASH | p-value for trend* |
|
---|---|---|---|---|---|
Patients/Women (N) |
24 / 20 | 28 / 20 | 15 / 10 | 16 / 13 | 0.58 |
Unadjusted | |||||
Activin A (pg/ml) | 356 ± 25 | 360 ± 20 | 407 ± 28 | 514 ± 70 | 0.010 |
Follistatin (ng/ml) | 1.11 ± 0.08 | 1.00 ± 0.07 | 0.86 ± 0.07 | 1.03 ± 0.04 | 0.13 |
Model 1 (adjusted mutually) | |||||
Activin A (pg/ml) | 359 ± 32 | 359 ± 29 | 401 ± 42 | 518 ± 40 | 0.009 |
Follistatin (ng/ml) | 1.09 ± 0.08 | 0.99 ± 0.07 | 0.85 ± 0.10 | 1.16 ± 0.10 | 0.13 |
Model 2 (adjusted mutually and for age) | |||||
Activin A (pg/ml) | 357 ± 31 | 365 ± 28 | 402 ± 40 | 509 ± 39 | 0.014 |
Follistatin (ng/ml) | 1.09 ± 0.08 | 1.00 ± 0.07 | 0.85 ± 0.10 | 1.16 ± 0.10 | 0.15 |
Model 3 (adjusted mutually and for age and gender) | |||||
Activin A (pg/ml) | 356 ± 31 | 365 ± 28 | 403 ± 41 | 509 ± 39 | 0.014 |
Follistatin (ng/ml) | 1.09 ± 0.08 | 1.00 ± 0.07 | 0.85 ± 0.10 | 1.16 ± 0.10 | 0.16 |
Model 4 (adjusted mutually and for age, gender and BMI) | |||||
Activin A (pg/ml) | 393 ± 25 | 359 ± 19 | 397 ± 28 | 405 ± 29 | 0.43 |
Follistatin (ng/ml) | 1.06 ± 0.10 | 1.02 ± 0.07 | 0.87 ± 0.11 | 1.19 ± 0.11 | 0.18 |
Model 5 (adjusted mutually and for age, gender and waist circumference) | |||||
Activin A (pg/ml) | 369 ± 28 | 363 ± 20 | 402 ± 30 | 410 ± 31 | 0.17 |
Follistatin (ng/ml) | 1.11 ± 0.10 | 1.00 ± 0.07 | 0.84 ± 0.11 | 1.12 ± 0.12 | 0.20 |
Model 6 (adjusted mutually and for age, gender and leptin) | |||||
Activin A (pg/ml) | 408 ± 28 | 369 ± 24 | 386 ± 35 | 438 ± 35 | 0.39 |
Follistatin (ng/ml) | 1.11 ± 0.09 | 1.00 ± 0.07 | 0.85 ± 0.10 | 1.14 ± 0.11 | 0.15 |
Data are estimated marginal mean ± standard error of the mean (SEM) or absolute numbers.
Between groups comparison (Analysis of covariance; ANCOVA).
Abbreviations: BMI, body mass index; NASH, nonalcoholic steatohepatitis; SS, simple steatosis.